Tumor expression of adiponectin receptor 2 and lethal prostate cancer.

TitleTumor expression of adiponectin receptor 2 and lethal prostate cancer.
Publication TypeJournal Article
Year of Publication2015
AuthorsRider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S
Corporate AuthorsTransdisciplinary Prostate Cancer Partnership(ToPCaP)
JournalCarcinogenesis
Volume36
Issue6
Pagination639-47
Date Published2015 Jun
ISSN1460-2180
KeywordsAdiponectin, Adult, Aged, Aged, 80 and over, Apoptosis, Biomarkers, Tumor, Cell Proliferation, Disease Progression, Fatty Acid Synthase, Type I, Humans, Ki-67 Antigen, Male, Middle Aged, Neovascularization, Pathologic, Obesity, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Receptors, Adiponectin
Abstract

To investigate the role of adiponectin receptor 2 (AdipoR2) in aggressive prostate cancer we used immunohistochemistry to characterize AdipoR2 protein expression in tumor tissue for 866 men with prostate cancer from the Physicians' Health Study and the Health Professionals Follow-up Study. AdipoR2 tumor expression was not associated with measures of obesity, pathological tumor stage or prostate-specific antigen (PSA) at diagnosis. However, AdipoR2 expression was positively associated with proliferation as measured by Ki-67 expression quartiles (P-trend < 0.0001), with expression of fatty acid synthase (P-trend = 0.001), and with two measures of angiogenesis (P-trend < 0.1). An inverse association was observed with apoptosis as assessed by the TUNEL assay (P-trend = 0.006). Using Cox proportional hazards regression and controlling for age at diagnosis, Gleason score, year of diagnosis category, cohort and baseline BMI, we identified a statistically significant trend for the association between quartile of AdipoR2 expression and lethal prostate cancer (P-trend = 0.02). The hazard ratio for lethal prostate cancer for the two highest quartiles, as compared to the two lowest quartiles, of AdipoR2 expression was 1.9 (95% confidence interval [CI]: 1.2-3.0). Results were similar when additionally controlling for categories of PSA at diagnosis and Ki-67 expression quartiles. These results strengthen the evidence for the role of AdipoR2 in prostate cancer progression.

DOI10.1093/carcin/bgv048
Alternate JournalCarcinogenesis
PubMed ID25863129
PubMed Central IDPMC4481603
Grant ListCA-40360 / CA / NCI NIH HHS / United States
CA-34944 / CA / NCI NIH HHS / United States
HL-34595 / HL / NHLBI NIH HHS / United States
P0126490 / / PHS HHS / United States
CA141298 / CA / NCI NIH HHS / United States
CA55075 / CA / NCI NIH HHS / United States
T32 GM074897 / GM / NIGMS NIH HHS / United States
5P50CA090381-08 / CA / NCI NIH HHS / United States
CA-097193 / CA / NCI NIH HHS / United States
P50 CA090381 / CA / NCI NIH HHS / United States
R35 CA197449 / CA / NCI NIH HHS / United States
CA13389 / CA / NCI NIH HHS / United States
T32 CA009001 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700